NCT06119269View on ClinicalTrials.gov

Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Myeloid Leukemia, Chronic Phase
Interventions
DIAGNOSTIC_TEST

Therapeutic drug monitoring

At each follow up visit, plasma concentrations of ponatinib will be measured and compared with therapeutic range (according to a lower concentration equal to 21 nM)

DIAGNOSTIC_TEST

Molecular Response

BCR-ABl transcript levels will be assessed to evaluate molecular response to ponatinib

Trial Locations (5)

20122

RECRUITING

Policlinico Milano, Milan

56126

RECRUITING

Santa Chiara University Hospital, Pisa

80131

RECRUITING

University of Naples Federico II - Unit of Hematology, Napoli

09124

RECRUITING

University of Cagliari - Businco Hospital - Unit of Hematology and Bone Marrow Transplant, Cagliari

00144

RECRUITING

Ospedale S. Eugenio ASL 2 Roma, Roma

All Listed Sponsors
lead

University of Pisa

OTHER